Clinical Trial Applications: Filter, Search, and view applications
| # | Protocol No | Study Title | Investigator(s) & Site(s) | |
|---|---|---|---|---|
156. |
ECCT/23/08/02 |
PRAISE An Adaptive, Randomized, Placebo-controlled, Double-blind, Multi-center Study of Oral FT-4202, a Pyruvate Kinase Activator in Patients with Sickle Cell Disease (PRAISE) |
Principal Investigator(s) 1. Nduba Videlis Site(s) in Kenya 1. Getrudes Children Hospital (Nairobi City county) 2. KEMRI/CRDR (Siaya county) 3.… read more |
View |
157. |
ECCT/23/01/02 |
PRAISE An Adaptive, Randomized, Placebo-controlled, Double-blind, Multi-center Study of Oral FT-4202, a Pyruvate Kinase Activator in Patients with Sickle Cell Disease (PRAISE) |
Principal Investigator(s) 1. Ogutu Bernhards Ragama Site(s) in Kenya 1. Kondele Children\'s Hospital Center for Clinical Research (CCR), (Kisumu county) 2… read more |
View |
158. |
ECCT/23/01/03 |
PRAISE An Adaptive, Randomized, Placebo-controlled, Double-blind, Multi-center Study of Oral FT-4202, a Pyruvate Kinase Activator in Patients with Sickle Cell Disease (PRAISE) |
Principal Investigator(s) 1. Githanga Githanga Nyokabi Site(s) in Kenya 1. Gertrude\'s Children Hospital (Nairobi City county) 2. Kondele Children\'s… read more |
View |
159. |
ECCT/14/09/01 | Extension to study MALARIA-055 PRI (110021) for evaluation of long-term efficacy, safety and immunogenicity of GSK Biologicals’candidate malaria vaccine (SB257049) in infants and children in Africa … read more |
Principal Investigator(s) 1. Walter Otieno Site(s) in Kenya Kenya Medical Research Institute/Walter Reed Project |
View |
160. |
ECCT/23/09/04 |
GBT440-038Open-Label Extension An Open-Label Extension Study of Voxelotor Administered Orally to Participants with Sickle Cell Disease Who Have Participated in Voxelotor Clinical Trials |
Principal Investigator(s) 1. Jessie Nyokabi Githanga 2. Videlis Nduba 3. Bernhards Ragama Ogutu Site(s) in Kenya 1. Gertrude’s Children Hospital (Nairobi… read more |
View |